Which region is the fastest-growing in the Transcatheter Aortic Valve Implantation (TAVI) Market?

Asia-Pacific is the fastest-growing region, expanding at a 12.8% CAGR from 2026 to 2035.

Which country holds the largest Transcatheter Aortic Valve Implantation (TAVI) Market share?

The U.S. holds the largest country-level share, with a market size of approximately USD 3.35 billion in 2025.

What are the key growth drivers of the Transcatheter Aortic Valve Implantation (TAVI) Market?

Expanding regulatory indications to asymptomatic severe aortic stenosis are a key driver, with the Native Aortic Stenosis indication segment alone generating USD 7.19 billion in 2025.

What factors restrain Transcatheter Aortic Valve Implantation (TAVI) Market growth?

High device and procedural costs relative to surgical alternatives restrain adoption, affecting cost-constrained health systems that account for a limited share of 2025 revenue.

What opportunities exist in the Transcatheter Aortic Valve Implantation (TAVI) Market?

Dedicated aortic regurgitation platforms and redo-TAVI compatibility present strong opportunities, with the Native Aortic Regurgitation segment growing at a 19.7% CAGR from 2026 to 2035.

How is technology influencing the Transcatheter Aortic Valve Implantation (TAVI) Market?

Alternative access route delivery systems are reshaping the market, with the Transcarotid access segment valued at USD 0.26 billion in 2025 and growing at a 17.7% CAGR from 2026 to 2035.

What regulatory environment shapes the Transcatheter Aortic Valve Implantation (TAVI) Market?

FDA requirements, EU Medical Device Regulation, and national reimbursement frameworks shape TAVI market access and adoption. North America accounted for approximately 46% of global TAVI revenue in 2025.

TAVI Market: USD 8.57B (2025) to USD 21.59B (2035)

Name: TAVI Market: USD 8.57B (2025) to USD 21.59B (2035)
Creator: Next Move Strategy Consulting
Published: 2025-06-24T00:00:00+00:00
License: https://www.nextmsc.com/privacy-policy

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2024 - 2030, MILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 DRIVER 1
  2. 5.1.2 DRIVER 2
  3. 5.1.3 DRIVER 3
  4. 5.1.4 DRIVER 4
3. 5.2 CHALLENGES
4. 1. 5.2.1 CHALLENGE 1
  2. 5.2.2 CHALLENGE 2
  3. 5.2.3 CHALLENGE 3
  4. 5.2.4 CHALLENGE 4
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 OPPORTUNITY 1
  2. 5.3.2 OPPORTUNITY 2

1. 6.1 OVERVIEW
2. 6.2 BALLOON-EXPANDABLE VALVES
3. 1. 6.2.1 BALLOON-EXPANDABLE VALVES MARKET, BY REGION
  2. 1. 6.2.1.1 NORTH AMERICA BALLOON-EXPANDABLE VALVES MARKET, BY COUNTRY
    2. 6.2.1.2 EUROPE BALLOON-EXPANDABLE VALVES MARKET, BY COUNTRY
    3. 6.2.1.3 ASIA-PACIFIC BALLOON-EXPANDABLE VALVES MARKET, BY COUNTRY
    4. 6.2.1.4 REST OF THE WORLD BALLOON-EXPANDABLE VALVES MARKET, BY COUNTRY
4. 6.3 SELF-EXPANDING VALVES
5. 1. 6.3.1 SELF-EXPANDING VALVES MARKET, BY REGION
  2. 1. 6.3.1.1 NORTH AMERICA SELF-EXPANDING VALVES MARKET, BY COUNTRY
    2. 6.3.1.2 EUROPE SELF-EXPANDING VALVES MARKET, BY COUNTRY
    3. 6.3.1.3 ASIA-PACIFIC SELF-EXPANDING VALVES MARKET, BY COUNTRY
    4. 6.3.1.4 REST OF THE WORLD SELF-EXPANDING VALVES MARKET, BY COUNTRY
6. 6.4 MECHANICALLY-EXPANDED VALVES
7. 1. 6.4.1 MECHANICALLY-EXPANDED VALVES MARKET, BY REGION
  2. 1. 6.4.1.1 NORTH AMERICA MECHANICALLY-EXPANDED VALVES MARKET, BY COUNTRY
    2. 6.4.1.2 EUROPE MECHANICALLY-EXPANDED VALVES MARKET, BY COUNTRY
    3. 6.4.1.3 ASIA-PACIFIC MECHANICALLY-EXPANDED VALVES MARKET, BY COUNTRY
    4. 6.4.1.4 REST OF THE WORLD MECHANICALLY-EXPANDED VALVES MARKET, BY COUNTRY

1. 7.1 OVERVIEW
2. 7.2 TRANSFEMORAL IMPLANTATION
3. 1. 7.2.1 TRANSFEMORAL IMPLANTATION MARKET, BY REGION
  2. 1. 7.2.1.1 NORTH AMERICA TRANSFEMORAL IMPLANTATION MARKET, BY COUNTRY
    2. 7.2.1.2 EUROPE TRANSFEMORAL IMPLANTATION MARKET, BY COUNTRY
    3. 7.2.1.3 ASIA-PACIFIC TRANSFEMORAL IMPLANTATION MARKET, BY COUNTRY
    4. 7.2.1.4 REST OF THE WORLD TRANSFEMORAL IMPLANTATION MARKET, BY COUNTRY
4. 7.3 TRANSAPICAL IMPLANTATION
5. 1. 7.3.1 TRANSAPICAL IMPLANTATION MARKET, BY REGION
  2. 1. 7.3.1.1 NORTH AMERICA TRANSAPICAL IMPLANTATION MARKET, BY COUNTRY
    2. 7.3.1.2 EUROPE TRANSAPICAL IMPLANTATION MARKET, BY COUNTRY
    3. 7.3.1.3 ASIA-PACIFIC TRANSAPICAL IMPLANTATION MARKET, BY COUNTRY
    4. 7.3.1.4 REST OF THE WORLD TRANSAPICAL IMPLANTATION MARKET, BY COUNTRY
6. 7.4 TRANSAORTIC IMPLANTATION
7. 1. 7.4.1 TRANSAORTIC IMPLANTATION MARKET, BY REGION
  2. 1. 7.4.1.1 NORTH AMERICA TRANSAORTIC IMPLANTATION MARKET, BY COUNTRY
    2. 7.4.1.2 EUROPE TRANSAORTIC IMPLANTATION MARKET, BY COUNTRY
    3. 7.4.1.3 ASIA-PACIFIC TRANSAORTIC IMPLANTATION MARKET, BY COUNTRY
    4. 7.4.1.4 REST OF THE WORLD TRANSAORTIC IMPLANTATION MARKET, BY COUNTRY

1. 8.1 OVERVIEW
2. 8.2 HIGH-RISK PATIENTS
3. 1. 8.2.1 HIGH-RISK PATIENTS MARKET, BY REGION
  2. 1. 8.2.1.1 NORTH AMERICA HIGH-RISK PATIENTS MARKET, BY COUNTRY
    2. 8.2.1.2 EUROPE HIGH-RISK PATIENTS MARKET, BY COUNTRY
    3. 8.2.1.3 ASIA-PACIFIC HIGH-RISK PATIENTS MARKET, BY COUNTRY
    4. 8.2.1.4 REST OF THE WORLD HIGH-RISK PATIENTS MARKET, BY COUNTRY
4. 8.3 INTERMEDIATE-RISK PATIENTS
5. 1. 8.3.1 INTERMEDIATE-RISK PATIENTS MARKET, BY REGION
  2. 1. 8.3.1.1 NORTH AMERICA INTERMEDIATE-RISK PATIENTS MARKET, BY COUNTRY
    2. 8.3.1.2 EUROPE INTERMEDIATE-RISK PATIENTS MARKET, BY COUNTRY
    3. 8.3.1.3 ASIA-PACIFIC INTERMEDIATE-RISK PATIENTS MARKET, BY COUNTRY
    4. 8.3.1.4 REST OF THE WORLD INTERMEDIATE-RISK PATIENTS MARKET, BY COUNTRY
6. 8.4 LOW-RISK PATIENTS
7. 1. 8.4.1 LOW-RISK PATIENTS MARKET, BY REGION
  2. 1. 8.4.1.1 NORTH AMERICA LOW-RISK PATIENTS MARKET, BY COUNTRY
    2. 8.4.1.2 EUROPE LOW-RISK PATIENTS MARKET, BY COUNTRY
    3. 8.4.1.3 ASIA-PACIFIC LOW-RISK PATIENTS MARKET, BY COUNTRY
    4. 8.4.1.4 REST OF THE WORLD LOW-RISK PATIENTS MARKET, BY COUNTRY

1. 9.1 OVERVIEW
2. 9.2 HOSPITALS
3. 1. 9.2.1 HOSPITALS MARKET, BY REGION
  2. 1. 9.2.1.1 NORTH AMERICA HOSPITALS MARKET, BY COUNTRY
    2. 9.2.1.2 EUROPE HOSPITALS MARKET, BY COUNTRY
    3. 9.2.1.3 ASIA-PACIFIC HOSPITALS MARKET, BY COUNTRY
    4. 9.2.1.4 REST OF THE WORLD HOSPITALS MARKET, BY COUNTRY
4. 9.3 CARDIAC CATHETERIZATION LABORATORIES
5. 1. 9.3.1 CARDIAC CATHETERIZATION LABORATORIES MARKET, BY REGION
  2. 1. 9.3.1.1 NORTH AMERICA CARDIAC CATHETERIZATION LABORATORIES MARKET, BY COUNTRY
    2. 9.3.1.2 EUROPE CARDIAC CATHETERIZATION LABORATORIES MARKET, BY COUNTRY
    3. 9.3.1.3 ASIA-PACIFIC CARDIAC CATHETERIZATION LABORATORIES MARKET, BY COUNTRY
    4. 9.3.1.4 REST OF THE WORLD CARDIAC CATHETERIZATION LABORATORIES MARKET, BY COUNTRY
6. 9.4 AMBULATORY SURGICAL CENTERS
7. 1. 9.4.1 AMBULATORY SURGICAL CENTERS MARKET, BY REGION
  2. 1. 9.4.1.1 NORTH AMERICA AMBULATORY SURGICAL CENTERS MARKET, BY COUNTRY
    2. 9.4.1.2 EUROPE AMBULATORY SURGICAL CENTERS MARKET, BY COUNTRY
    3. 9.4.1.3 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS MARKET, BY COUNTRY
    4. 9.4.1.4 REST OF THE WORLD AMBULATORY SURGICAL CENTERS MARKET, BY COUNTRY

1. 10.1 OVERVIEW
2. 10.2 NORTH AMERICA
3. 1. 10.2.1 NORTH AMERICA TAVI MARKET, BY PRODUCT TYPE
  2. 10.2.2 NORTH AMERICA TAVI MARKET, BY PROCEDURE
  3. 10.2.3 NORTH AMERICA TAVI MARKET, BY PATIENT GROUP
  4. 10.2.4 NORTH AMERICA TAVI MARKET, BY END USER
  5. 10.2.5 NORTH AMERICA TAVI MARKET, BY COUNTRY
  6. 1. 10.2.5.1 UNITED STATES
    2. 1. 10.2.5.1.1 UNITED STATES TAVI MARKET, BY PRODUCT TYPE
      2. 10.2.5.1.2 UNITED STATES TAVI MARKET, BY PROCEDURE
      3. 10.2.5.1.3 UNITED STATES TAVI MARKET, BY PATIENT GROUP
      4. 10.2.5.1.4 UNITED STATES TAVI MARKET, BY END USER
    3. 10.2.5.2 CANADA
    4. 1. 10.2.5.2.1 CANADA TAVI MARKET, BY PRODUCT TYPE
      2. 10.2.5.2.2 CANADA TAVI MARKET, BY PROCEDURE
      3. 10.2.5.2.3 CANADA TAVI MARKET, BY PATIENT GROUP
      4. 10.2.5.2.4 CANADA TAVI MARKET, BY END USER
    5. 10.2.5.3 MEXICO
    6. 1. 10.2.5.3.1 MEXICO TAVI MARKET, BY PRODUCT TYPE
      2. 10.2.5.3.2 MEXICO TAVI MARKET, BY PROCEDURE
      3. 10.2.5.3.3 MEXICO TAVI MARKET, BY PATIENT GROUP
      4. 10.2.5.3.4 MEXICO TAVI MARKET, BY END USER
4. 10.3 EUROPE
5. 1. 10.3.1 EUROPE TAVI MARKET, BY PRODUCT TYPE
  2. 10.3.2 EUROPE TAVI MARKET, BY PROCEDURE
  3. 10.3.3 EUROPE TAVI MARKET, BY PATIENT GROUP
  4. 10.3.4 EUROPE TAVI MARKET, BY END USER
  5. 10.3.5 EUROPE TAVI MARKET, BY COUNTRY
  6. 1. 10.3.5.1 GERMANY
    2. 1. 10.3.5.1.1 GERMANY TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.1.2 GERMANY TAVI MARKET, BY PROCEDURE
      3. 10.3.5.1.3 GERMANY TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.1.4 GERMANY TAVI MARKET, BY END USER
    3. 10.3.5.2 FRANCE
    4. 1. 10.3.5.2.1 FRANCE TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.2.2 FRANCE TAVI MARKET, BY PROCEDURE
      3. 10.3.5.2.3 FRANCE TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.2.4 FRANCE TAVI MARKET, BY END USER
    5. 10.3.5.3 ITALY
    6. 1. 10.3.5.3.1 ITALY TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.3.2 ITALY TAVI MARKET, BY PROCEDURE
      3. 10.3.5.3.3 ITALY TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.3.4 ITALY TAVI MARKET, BY END USER
    7. 10.3.5.4 SPAIN
    8. 1. 10.3.5.4.1 SPAIN TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.4.2 SPAIN TAVI MARKET, BY PROCEDURE
      3. 10.3.5.4.3 SPAIN TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.4.4 SPAIN TAVI MARKET, BY END USER
    9. 10.3.5.5 UNITED KINGDOM
    10. 1. 10.3.5.5.1 UNITED KINGDOM TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.5.2 UNITED KINGDOM TAVI MARKET, BY PROCEDURE
      3. 10.3.5.5.3 UNITED KINGDOM TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.5.4 UNITED KINGDOM TAVI MARKET, BY END USER
    11. 10.3.5.6 RUSSIA
    12. 1. 10.3.5.6.1 RUSSIA TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.6.2 RUSSIA TAVI MARKET, BY PROCEDURE
      3. 10.3.5.6.3 RUSSIA TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.6.4 RUSSIA TAVI MARKET, BY END USER
    13. 10.3.5.7 SWEDEN
    14. 1. 10.3.5.7.1 SWEDEN TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.7.2 SWEDEN TAVI MARKET, BY PROCEDURE
      3. 10.3.5.7.3 SWEDEN TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.7.4 SWEDEN TAVI MARKET, BY END USER
    15. 10.3.5.8 NORWAY
    16. 1. 10.3.5.8.1 NORWAY TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.8.2 NORWAY TAVI MARKET, BY PROCEDURE
      3. 10.3.5.8.3 NORWAY TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.8.4 NORWAY TAVI MARKET, BY END USER
    17. 10.3.5.9 DENMARK
    18. 1. 10.3.5.9.1 DENMARK TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.9.2 DENMARK TAVI MARKET, BY PROCEDURE
      3. 10.3.5.9.3 DENMARK TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.9.4 DENMARK TAVI MARKET, BY END USER
    19. 10.3.5.10 NETHERLANDS
    20. 1. 10.3.5.10.1 NETHERLANDS TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.10.2 NETHERLANDS TAVI MARKET, BY PROCEDURE
      3. 10.3.5.10.3 NETHERLANDS TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.10.4 NETHERLANDS TAVI MARKET, BY END USER
    21. 10.3.5.11 FINLAND
    22. 1. 10.3.5.11.1 FINLAND TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.11.2 FINLAND TAVI MARKET, BY PROCEDURE
      3. 10.3.5.11.3 FINLAND TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.11.4 FINLAND TAVI MARKET, BY END USER
    23. 10.3.5.12 REST OF EUROPE
    24. 1. 10.3.5.12.1 REST OF EUROPE TAVI MARKET, BY PRODUCT TYPE
      2. 10.3.5.12.2 REST OF EUROPE TAVI MARKET, BY PROCEDURE
      3. 10.3.5.12.3 REST OF EUROPE TAVI MARKET, BY PATIENT GROUP
      4. 10.3.5.12.4 REST OF EUROPE TAVI MARKET, BY END USER
6. 10.4 ASIA-PACIFIC
7. 1. 10.4.1 ASIA-PACIFIC TAVI MARKET, BY PRODUCT TYPE
  2. 10.4.2 ASIA-PACIFIC TAVI MARKET, BY PROCEDURE
  3. 10.4.3 ASIA-PACIFIC TAVI MARKET, BY PATIENT GROUP
  4. 10.4.4 ASIA-PACIFIC TAVI MARKET, BY END USER
  5. 10.4.5 ASIA-PACIFIC TAVI MARKET, BY COUNTRY
  6. 1. 10.4.5.1 AUSTRALIA
    2. 1. 10.4.5.1.1 AUSTRALIA TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.1.2 AUSTRALIA TAVI MARKET, BY PROCEDURE
      3. 10.4.5.1.3 AUSTRALIA TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.1.4 AUSTRALIA TAVI MARKET, BY END USER
    3. 10.4.5.2 CHINA
    4. 1. 10.4.5.2.1 CHINA TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.2.2 CHINA TAVI MARKET, BY PROCEDURE
      3. 10.4.5.2.3 CHINA TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.2.4 CHINA TAVI MARKET, BY END USER
    5. 10.4.5.3 INDIA
    6. 1. 10.4.5.3.1 INDIA TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.3.2 INDIA TAVI MARKET, BY PROCEDURE
      3. 10.4.5.3.3 INDIA TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.3.4 INDIA TAVI MARKET, BY END USER
    7. 10.4.5.4 JAPAN
    8. 1. 10.4.5.4.1 JAPAN TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.4.2 JAPAN TAVI MARKET, BY PROCEDURE
      3. 10.4.5.4.3 JAPAN TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.4.4 JAPAN TAVI MARKET, BY END USER
    9. 10.4.5.5 SOUTH KOREA
    10. 1. 10.4.5.5.1 SOUTH KOREA TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.5.2 SOUTH KOREA TAVI MARKET, BY PROCEDURE
      3. 10.4.5.5.3 SOUTH KOREA TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.5.4 SOUTH KOREA TAVI MARKET, BY END USER
    11. 10.4.5.6 INDONESIA
    12. 1. 10.4.5.6.1 INDONESIA TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.6.2 INDONESIA TAVI MARKET, BY PROCEDURE
      3. 10.4.5.6.3 INDONESIA TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.6.4 INDONESIA TAVI MARKET, BY END USER
    13. 10.4.5.7 SINGAPORE
    14. 1. 10.4.5.7.1 SINGAPORE TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.7.2 SINGAPORE TAVI MARKET, BY PROCEDURE
      3. 10.4.5.7.3 SINGAPORE TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.7.4 SINGAPORE TAVI MARKET, BY END USER
    15. 10.4.5.8 TAIWAN
    16. 1. 10.4.5.8.1 TAIWAN TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.8.2 TAIWAN TAVI MARKET, BY PROCEDURE
      3. 10.4.5.8.3 TAIWAN TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.8.4 TAIWAN TAVI MARKET, BY END USER
    17. 10.4.5.9 THAILAND
    18. 1. 10.4.5.9.1 THAILAND TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.9.2 THAILAND TAVI MARKET, BY PROCEDURE
      3. 10.4.5.9.3 THAILAND TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.9.4 THAILAND TAVI MARKET, BY END USER
    19. 10.4.5.10 REST OF ASIA-PACIFIC
    20. 1. 10.4.5.10.1 REST OF ASIA-PACIFIC TAVI MARKET, BY PRODUCT TYPE
      2. 10.4.5.10.2 REST OF ASIA-PACIFIC TAVI MARKET, BY PROCEDURE
      3. 10.4.5.10.3 REST OF ASIA-PACIFIC TAVI MARKET, BY PATIENT GROUP
      4. 10.4.5.10.4 REST OF ASIA-PACIFIC TAVI MARKET, BY END USER
8. 10.5 REST OF THE WORLD
9. 1. 10.5.1 REST OF THE WORLD TAVI MARKET, BY PRODUCT TYPE
  2. 10.5.2 REST OF THE WORLD TAVI MARKET, BY PROCEDURE
  3. 10.5.3 REST OF THE WORLD TAVI MARKET, BY PATIENT GROUP
  4. 10.5.4 REST OF THE WORLD TAVI MARKET, BY END USER
  5. 10.5.5 REST OF THE WORLD TAVI MARKET, BY COUNTRY
  6. 1. 10.5.5.1 LATIN AMERICA
    2. 1. 10.5.5.1.1 LATIN AMERICA TAVI MARKET, BY PRODUCT TYPE
      2. 10.5.5.1.2 LATIN AMERICA TAVI MARKET, BY PROCEDURE
      3. 10.5.5.1.3 LATIN AMERICA TAVI MARKET, BY PATIENT GROUP
      4. 10.5.5.1.4 LATIN AMERICA TAVI MARKET, BY END USER
    3. 10.5.5.2 MIDDLE EAST
    4. 1. 10.5.5.2.1 MIDDLE EAST TAVI MARKET, BY PRODUCT TYPE
      2. 10.5.5.2.2 MIDDLE EAST TAVI MARKET, BY PROCEDURE
      3. 10.5.5.2.3 MIDDLE EAST TAVI MARKET, BY PATIENT GROUP
      4. 10.5.5.2.4 MIDDLE EAST TAVI MARKET, BY END USER
    5. 10.5.5.3 AFRICA
    6. 1. 10.5.5.3.1 AFRICA TAVI MARKET, BY PRODUCT TYPE
      2. 10.5.5.3.2 AFRICA TAVI MARKET, BY PROCEDURE
      3. 10.5.5.3.3 AFRICA TAVI MARKET, BY PATIENT GROUP
      4. 10.5.5.3.4 AFRICA TAVI MARKET, BY END USER

1. 11.1 ABBOTT LABORATORIES
2. 1. 11.1.1 COMPANY OVERVIEW
  2. 11.1.2 COMPANY SNAPSHOT
  3. 11.1.3 OPERATING BUSINESS SEGMENTS
  4. 11.1.4 PRODUCT PORTFOLIO
  5. 11.1.5 BUSINESS PERFORMANCE
  6. 11.1.6 BUSINESS SEGMENTS
  7. 11.1.7 GEOGRAPHIC SEGMENTS
  8. 11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.1.9 PRIMARY MARKET COMPETITORS
3. 11.2 MERIL LIFE SCIENCES PVT. LTD.
4. 1. 11.2.1 COMPANY OVERVIEW
  2. 11.2.2 COMPANY SNAPSHOT
  3. 11.2.3 OPERATING BUSINESS SEGMENTS
  4. 11.2.4 PRODUCT PORTFOLIO
  5. 11.2.5 BUSINESS PERFORMANCE
  6. 11.2.6 BUSINESS SEGMENTS
  7. 11.2.7 GEOGRAPHIC SEGMENTS
  8. 11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.2.9 PRIMARY MARKET COMPETITORS
5. 11.3 BOSTON SCIENTIFIC CORPORATION
6. 1. 11.3.1 COMPANY OVERVIEW
  2. 11.3.2 COMPANY SNAPSHOT
  3. 11.3.3 OPERATING BUSINESS SEGMENTS
  4. 11.3.4 PRODUCT PORTFOLIO
  5. 11.3.5 BUSINESS PERFORMANCE
  6. 11.3.6 BUSINESS SEGMENTS
  7. 11.3.7 GEOGRAPHIC SEGMENTS
  8. 11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.3.9 PRIMARY MARKET COMPETITORS
7. 11.4 LEPU MEDICAL TECHNOLOGY CO., LTD.
8. 1. 11.4.1 COMPANY OVERVIEW
  2. 11.4.2 COMPANY SNAPSHOT
  3. 11.4.3 OPERATING BUSINESS SEGMENTS
  4. 11.4.4 PRODUCT PORTFOLIO
  5. 11.4.5 BUSINESS PERFORMANCE
  6. 11.4.6 BUSINESS SEGMENTS
  7. 11.4.7 GEOGRAPHIC SEGMENTS
  8. 11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.4.9 PRIMARY MARKET COMPETITORS
9. 11.5 NEW VALVE TECHNOLOGY (NVT) GMBH
10. 1. 11.5.1 COMPANY OVERVIEW
  2. 11.5.2 COMPANY SNAPSHOT
  3. 11.5.3 OPERATING BUSINESS SEGMENTS
  4. 11.5.4 PRODUCT PORTFOLIO
  5. 11.5.5 BUSINESS PERFORMANCE
  6. 11.5.6 BUSINESS SEGMENTS
  7. 11.5.7 GEOGRAPHIC SEGMENTS
  8. 11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.5.9 PRIMARY MARKET COMPETITORS
11. 11.6 MEDTRONIC PLC
12. 1. 11.6.1 COMPANY OVERVIEW
  2. 11.6.2 COMPANY SNAPSHOT
  3. 11.6.3 OPERATING BUSINESS SEGMENTS
  4. 11.6.4 PRODUCT PORTFOLIO
  5. 11.6.5 BUSINESS PERFORMANCE
  6. 11.6.6 BUSINESS SEGMENTS
  7. 11.6.7 GEOGRAPHIC SEGMENTS
  8. 11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.6.9 PRIMARY MARKET COMPETITORS
13. 11.7 VENUS MEDTECH INC.
14. 1. 11.7.1 COMPANY OVERVIEW
  2. 11.7.2 COMPANY SNAPSHOT
  3. 11.7.3 OPERATING BUSINESS SEGMENTS
  4. 11.7.4 PRODUCT PORTFOLIO
  5. 11.7.5 BUSINESS PERFORMANCE
  6. 11.7.6 BUSINESS SEGMENTS
  7. 11.7.7 GEOGRAPHIC SEGMENTS
  8. 11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.7.9 PRIMARY MARKET COMPETITORS
15. 11.8 EDWARDS LIFESCIENCES CORPORATION
16. 1. 11.8.1 COMPANY OVERVIEW
  2. 11.8.2 COMPANY SNAPSHOT
  3. 11.8.3 OPERATING BUSINESS SEGMENTS
  4. 11.8.4 PRODUCT PORTFOLIO
  5. 11.8.5 BUSINESS PERFORMANCE
  6. 11.8.6 BUSINESS SEGMENTS
  7. 11.8.7 GEOGRAPHIC SEGMENTS
  8. 11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.8.9 PRIMARY MARKET COMPETITORS
17. 11.9 MICROPORT SCIENTIFIC CORPORATION
18. 1. 11.9.1 COMPANY OVERVIEW
  2. 11.9.2 COMPANY SNAPSHOT
  3. 11.9.3 OPERATING BUSINESS SEGMENTS
  4. 11.9.4 PRODUCT PORTFOLIO
  5. 11.9.5 BUSINESS PERFORMANCE
  6. 11.9.6 BUSINESS SEGMENTS
  7. 11.9.7 GEOGRAPHIC SEGMENTS
  8. 11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.9.9 PRIMARY MARKET COMPETITORS
19. 11.10 PEIJIA MEDICAL TECHNOLOGY CO., LTD.
20. 1. 11.10.1 COMPANY OVERVIEW
  2. 11.10.2 COMPANY SNAPSHOT
  3. 11.10.3 OPERATING BUSINESS SEGMENTS
  4. 11.10.4 PRODUCT PORTFOLIO
  5. 11.10.5 BUSINESS PERFORMANCE
  6. 11.10.6 BUSINESS SEGMENTS
  7. 11.10.7 GEOGRAPHIC SEGMENTS
  8. 11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.10.9 PRIMARY MARKET COMPETITORS
21. 11.11 JENAVALVE TECHNOLOGY, INC.
22. 1. 11.11.1 COMPANY OVERVIEW
  2. 11.11.2 COMPANY SNAPSHOT
  3. 11.11.3 OPERATING BUSINESS SEGMENTS
  4. 11.11.4 PRODUCT PORTFOLIO
  5. 11.11.5 BUSINESS PERFORMANCE
  6. 11.11.6 BUSINESS SEGMENTS
  7. 11.11.7 GEOGRAPHIC SEGMENTS
  8. 11.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.11.9 PRIMARY MARKET COMPETITORS
23. 11.12 ANTERIS TECHNOLOGIES
24. 1. 11.12.1 COMPANY OVERVIEW
  2. 11.12.2 COMPANY SNAPSHOT
  3. 11.12.3 OPERATING BUSINESS SEGMENTS
  4. 11.12.4 PRODUCT PORTFOLIO
  5. 11.12.5 BUSINESS PERFORMANCE
  6. 11.12.6 BUSINESS SEGMENTS
  7. 11.12.7 GEOGRAPHIC SEGMENTS
  8. 11.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.12.9 PRIMARY MARKET COMPETITORS
25. 11.13 SHANGHAI NEWMED MEDICAL CO., LTD.
26. 1. 11.13.1 COMPANY OVERVIEW
  2. 11.13.2 COMPANY SNAPSHOT
  3. 11.13.3 OPERATING BUSINESS SEGMENTS
  4. 11.13.4 PRODUCT PORTFOLIO
  5. 11.13.5 BUSINESS PERFORMANCE
  6. 11.13.6 BUSINESS SEGMENTS
  7. 11.13.7 GEOGRAPHIC SEGMENTS
  8. 11.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.13.9 PRIMARY MARKET COMPETITORS
27. 11.14 COLIBRI HEART VALVE LLC
28. 1. 11.14.1 COMPANY OVERVIEW
  2. 11.14.2 COMPANY SNAPSHOT
  3. 11.14.3 OPERATING BUSINESS SEGMENTS
  4. 11.14.4 PRODUCT PORTFOLIO
  5. 11.14.5 BUSINESS PERFORMANCE
  6. 11.14.6 BUSINESS SEGMENTS
  7. 11.14.7 GEOGRAPHIC SEGMENTS
  8. 11.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.14.9 PRIMARY MARKET COMPETITORS
29. 11.15 THUBRIKAR AORTIC VALVE, INC.
30. 1. 11.15.1 COMPANY OVERVIEW
  2. 11.15.2 COMPANY SNAPSHOT
  3. 11.15.3 OPERATING BUSINESS SEGMENTS
  4. 11.15.4 PRODUCT PORTFOLIO
  5. 11.15.5 BUSINESS PERFORMANCE
  6. 11.15.6 BUSINESS SEGMENTS
  7. 11.15.7 GEOGRAPHIC SEGMENTS
  8. 11.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. GLOBAL TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 2. BALLOON-EXPANDABLE VALVES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 3. NORTH AMERICA BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 4. EUROPE BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 5. ASIA-PACIFIC BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 6. REST OF THE WORLD BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 7. SELF-EXPANDING VALVES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 8. NORTH AMERICA SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 9. EUROPE SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 10. ASIA-PACIFIC SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 11. REST OF THE WORLD SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 12. MECHANICALLY-EXPANDED VALVES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 13. NORTH AMERICA MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 14. EUROPE MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 15. ASIA-PACIFIC MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 16. REST OF THE WORLD MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 17. GLOBAL TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 18. TRANSFEMORAL IMPLANTATION MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 19. NORTH AMERICA TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 20. EUROPE TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 21. ASIA-PACIFIC TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 22. REST OF THE WORLD TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 23. TRANSAPICAL IMPLANTATION MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 24. NORTH AMERICA TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 25. EUROPE TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 26. ASIA-PACIFIC TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 27. REST OF THE WORLD TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 28. TRANSAORTIC IMPLANTATION MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 29. NORTH AMERICA TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 30. EUROPE TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 31. ASIA-PACIFIC TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 32. REST OF THE WORLD TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 33. GLOBAL TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 34. HIGH-RISK PATIENTS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 35. NORTH AMERICA HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 36. EUROPE HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 37. ASIA-PACIFIC HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 38. REST OF THE WORLD HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 39. INTERMEDIATE-RISK PATIENTS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 40. NORTH AMERICA INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 41. EUROPE INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 42. ASIA-PACIFIC INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 43. REST OF THE WORLD INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 44. LOW-RISK PATIENTS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 45. NORTH AMERICA LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 46. EUROPE LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 47. ASIA-PACIFIC LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 48. REST OF THE WORLD LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 49. GLOBAL TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 50. HOSPITALS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 51. NORTH AMERICA HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 52. EUROPE HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 53. ASIA-PACIFIC HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 54. REST OF THE WORLD HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 55. CARDIAC CATHETERIZATION LABORATORIES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 56. NORTH AMERICA CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 57. EUROPE CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 58. ASIA-PACIFIC CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 59. REST OF THE WORLD CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 60. AMBULATORY SURGICAL CENTERS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 61. NORTH AMERICA AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 62. EUROPE AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 63. ASIA-PACIFIC AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 64. REST OF THE WORLD AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
TABLE 65. GLOBAL TAVI MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
TABLE 66. NORTH AMERICA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 67. NORTH AMERICA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 68. NORTH AMERICA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 69. NORTH AMERICA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 70. UNITED STATES TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 71. UNITED STATES TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 72. UNITED STATES TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 73. UNITED STATES TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 74. CANADA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 75. CANADA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 76. CANADA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 77. CANADA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 78. MEXICO TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 79. MEXICO TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 80. MEXICO TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 81. MEXICO TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 82. EUROPE TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 83. EUROPE TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 84. EUROPE TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 85. EUROPE TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 86. GERMANY TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 87. GERMANY TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 88. GERMANY TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 89. GERMANY TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 90. FRANCE TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 91. FRANCE TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 92. FRANCE TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 93. FRANCE TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 94. ITALY TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 95. ITALY TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 96. ITALY TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 97. ITALY TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 98. SPAIN TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 99. SPAIN TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 100. SPAIN TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 101. SPAIN TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 102. UNITED KINGDOM TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 103. UNITED KINGDOM TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 104. UNITED KINGDOM TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 105. UNITED KINGDOM TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 106. RUSSIA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 107. RUSSIA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 108. RUSSIA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 109. RUSSIA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 110. SWEDEN TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 111. SWEDEN TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 112. SWEDEN TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 113. SWEDEN TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 114. NORWAY TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 115. NORWAY TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 116. NORWAY TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 117. NORWAY TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 118. DENMARK TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 119. DENMARK TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 120. DENMARK TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 121. DENMARK TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 122. NETHERLANDS TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 123. NETHERLANDS TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 124. NETHERLANDS TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 125. NETHERLANDS TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 126. FINLAND TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 127. FINLAND TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 128. FINLAND TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 129. FINLAND TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 130. REST OF EUROPE TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 131. REST OF EUROPE TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 132. REST OF EUROPE TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 133. REST OF EUROPE TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 134. ASIA-PACIFIC TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 135. ASIA-PACIFIC TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 136. ASIA-PACIFIC TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 137. ASIA-PACIFIC TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 138. AUSTRALIA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 139. AUSTRALIA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 140. AUSTRALIA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 141. AUSTRALIA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 142. CHINA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 143. CHINA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 144. CHINA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 145. CHINA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 146. INDIA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 147. INDIA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 148. INDIA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 149. INDIA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 150. JAPAN TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 151. JAPAN TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 152. JAPAN TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 153. JAPAN TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 154. SOUTH KOREA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 155. SOUTH KOREA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 156. SOUTH KOREA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 157. SOUTH KOREA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 158. INDONESIA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 159. INDONESIA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 160. INDONESIA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 161. INDONESIA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 162. SINGAPORE TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 163. SINGAPORE TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 164. SINGAPORE TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 165. SINGAPORE TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 166. TAIWAN TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 167. TAIWAN TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 168. TAIWAN TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 169. TAIWAN TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 170. THAILAND TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 171. THAILAND TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 172. THAILAND TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 173. THAILAND TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 174. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 175. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 176. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 177. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 178. REST OF THE WORLD TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 179. REST OF THE WORLD TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 180. REST OF THE WORLD TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 181. REST OF THE WORLD TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 182. LATIN AMERICA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 183. LATIN AMERICA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 184. LATIN AMERICA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 185. LATIN AMERICA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 186. MIDDLE EAST TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 187. MIDDLE EAST TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 188. MIDDLE EAST TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 189. MIDDLE EAST TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 190. AFRICA TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 191. AFRICA TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
TABLE 192. AFRICA TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
TABLE 193. AFRICA TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
TABLE 194. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 195. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 196. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 197. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 198. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 199. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 200. MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
TABLE 201. MERIL LIFE SCIENCES PVT. LTD.: OPERATING BUSINESS SEGMENTS
TABLE 202. MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
TABLE 203. MERIL LIFE SCIENCES PVT. LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 204. MERIL LIFE SCIENCES PVT. LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 205. MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGY
TABLE 206. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 207. BOSTON SCIENTIFIC CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 208. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 209. BOSTON SCIENTIFIC CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 210. BOSTON SCIENTIFIC CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 211. BOSTON SCIENTIFIC CORPORATION: KEY STRATERGY
TABLE 212. LEPU MEDICAL TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
TABLE 213. LEPU MEDICAL TECHNOLOGY CO., LTD.: OPERATING BUSINESS SEGMENTS
TABLE 214. LEPU MEDICAL TECHNOLOGY CO., LTD.: PRODUCT PORTFOLIO
TABLE 215. LEPU MEDICAL TECHNOLOGY CO., LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 216. LEPU MEDICAL TECHNOLOGY CO., LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 217. LEPU MEDICAL TECHNOLOGY CO., LTD.: KEY STRATERGY
TABLE 218. NEW VALVE TECHNOLOGY (NVT) GMBH: COMPANY SNAPSHOT
TABLE 219. NEW VALVE TECHNOLOGY (NVT) GMBH: OPERATING BUSINESS SEGMENTS
TABLE 220. NEW VALVE TECHNOLOGY (NVT) GMBH: PRODUCT PORTFOLIO
TABLE 221. NEW VALVE TECHNOLOGY (NVT) GMBH: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 222. NEW VALVE TECHNOLOGY (NVT) GMBH: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 223. NEW VALVE TECHNOLOGY (NVT) GMBH: KEY STRATERGY
TABLE 224. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 225. MEDTRONIC PLC: OPERATING BUSINESS SEGMENTS
TABLE 226. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 227. MEDTRONIC PLC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 228. MEDTRONIC PLC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 229. MEDTRONIC PLC: KEY STRATERGY
TABLE 230. VENUS MEDTECH INC.: COMPANY SNAPSHOT
TABLE 231. VENUS MEDTECH INC.: OPERATING BUSINESS SEGMENTS
TABLE 232. VENUS MEDTECH INC.: PRODUCT PORTFOLIO
TABLE 233. VENUS MEDTECH INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 234. VENUS MEDTECH INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 235. VENUS MEDTECH INC.: KEY STRATERGY
TABLE 236. EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT
TABLE 237. EDWARDS LIFESCIENCES CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 238. EDWARDS LIFESCIENCES CORPORATION: PRODUCT PORTFOLIO
TABLE 239. EDWARDS LIFESCIENCES CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 240. EDWARDS LIFESCIENCES CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 241. EDWARDS LIFESCIENCES CORPORATION: KEY STRATERGY
TABLE 242. MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 243. MICROPORT SCIENTIFIC CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 244. MICROPORT SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 245. MICROPORT SCIENTIFIC CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 246. MICROPORT SCIENTIFIC CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 247. MICROPORT SCIENTIFIC CORPORATION: KEY STRATERGY
TABLE 248. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
TABLE 249. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: OPERATING BUSINESS SEGMENTS
TABLE 250. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: PRODUCT PORTFOLIO
TABLE 251. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 252. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 253. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: KEY STRATERGY
TABLE 254. JENAVALVE TECHNOLOGY, INC.: COMPANY SNAPSHOT
TABLE 255. JENAVALVE TECHNOLOGY, INC.: OPERATING BUSINESS SEGMENTS
TABLE 256. JENAVALVE TECHNOLOGY, INC.: PRODUCT PORTFOLIO
TABLE 257. JENAVALVE TECHNOLOGY, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 258. JENAVALVE TECHNOLOGY, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 259. JENAVALVE TECHNOLOGY, INC.: KEY STRATERGY
TABLE 260. ANTERIS TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 261. ANTERIS TECHNOLOGIES: OPERATING BUSINESS SEGMENTS
TABLE 262. ANTERIS TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 263. ANTERIS TECHNOLOGIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 264. ANTERIS TECHNOLOGIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 265. ANTERIS TECHNOLOGIES: KEY STRATERGY
TABLE 266. SHANGHAI NEWMED MEDICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 267. SHANGHAI NEWMED MEDICAL CO., LTD.: OPERATING BUSINESS SEGMENTS
TABLE 268. SHANGHAI NEWMED MEDICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 269. SHANGHAI NEWMED MEDICAL CO., LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 270. SHANGHAI NEWMED MEDICAL CO., LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 271. SHANGHAI NEWMED MEDICAL CO., LTD.: KEY STRATERGY
TABLE 272. COLIBRI HEART VALVE LLC: COMPANY SNAPSHOT
TABLE 273. COLIBRI HEART VALVE LLC: OPERATING BUSINESS SEGMENTS
TABLE 274. COLIBRI HEART VALVE LLC: PRODUCT PORTFOLIO
TABLE 275. COLIBRI HEART VALVE LLC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 276. COLIBRI HEART VALVE LLC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 277. COLIBRI HEART VALVE LLC: KEY STRATERGY
TABLE 278. THUBRIKAR AORTIC VALVE, INC.: COMPANY SNAPSHOT
TABLE 279. THUBRIKAR AORTIC VALVE, INC.: OPERATING BUSINESS SEGMENTS
TABLE 280. THUBRIKAR AORTIC VALVE, INC.: PRODUCT PORTFOLIO
TABLE 281. THUBRIKAR AORTIC VALVE, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 282. THUBRIKAR AORTIC VALVE, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 283. THUBRIKAR AORTIC VALVE, INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. GLOBAL TAVI MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
FIGURE 7. BALLOON-EXPANDABLE VALVES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 8. NORTH AMERICA BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 9. EUROPE BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 10. ASIA-PACIFIC BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 11. REST OF THE WORLD BALLOON-EXPANDABLE VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 12. SELF-EXPANDING VALVES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 13. NORTH AMERICA SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 14. EUROPE SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 15. ASIA-PACIFIC SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 16. REST OF THE WORLD SELF-EXPANDING VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 17. MECHANICALLY-EXPANDED VALVES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 18. NORTH AMERICA MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 19. EUROPE MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 20. ASIA-PACIFIC MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 21. REST OF THE WORLD MECHANICALLY-EXPANDED VALVES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 22. GLOBAL TAVI MARKET VALUE, BY PROCEDURE, 2024-2030, (MILLION USD)
FIGURE 23. TRANSFEMORAL IMPLANTATION MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 24. NORTH AMERICA TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 25. EUROPE TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 26. ASIA-PACIFIC TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 27. REST OF THE WORLD TRANSFEMORAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 28. TRANSAPICAL IMPLANTATION MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 29. NORTH AMERICA TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 30. EUROPE TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 31. ASIA-PACIFIC TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 32. REST OF THE WORLD TRANSAPICAL IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 33. TRANSAORTIC IMPLANTATION MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 34. NORTH AMERICA TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 35. EUROPE TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 36. ASIA-PACIFIC TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 37. REST OF THE WORLD TRANSAORTIC IMPLANTATION, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 38. GLOBAL TAVI MARKET VALUE, BY PATIENT GROUP, 2024-2030, (MILLION USD)
FIGURE 39. HIGH-RISK PATIENTS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 40. NORTH AMERICA HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 41. EUROPE HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 42. ASIA-PACIFIC HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 43. REST OF THE WORLD HIGH-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 44. INTERMEDIATE-RISK PATIENTS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 45. NORTH AMERICA INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 46. EUROPE INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 47. ASIA-PACIFIC INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 48. REST OF THE WORLD INTERMEDIATE-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 49. LOW-RISK PATIENTS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 50. NORTH AMERICA LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 51. EUROPE LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 52. ASIA-PACIFIC LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 53. REST OF THE WORLD LOW-RISK PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 54. GLOBAL TAVI MARKET VALUE, BY END USER, 2024-2030, (MILLION USD)
FIGURE 55. HOSPITALS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 56. NORTH AMERICA HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 57. EUROPE HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 58. ASIA-PACIFIC HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 59. REST OF THE WORLD HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 60. CARDIAC CATHETERIZATION LABORATORIES MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 61. NORTH AMERICA CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 62. EUROPE CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 63. ASIA-PACIFIC CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 64. REST OF THE WORLD CARDIAC CATHETERIZATION LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 65. AMBULATORY SURGICAL CENTERS MARKET VALUE, BY REGION, 2024-2030, (MILLION USD)
FIGURE 66. NORTH AMERICA AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 67. EUROPE AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 68. ASIA-PACIFIC AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 69. REST OF THE WORLD AMBULATORY SURGICAL CENTERS, MARKET VALUE, BY COUNTRY, 2024-2030, (MILLION USD)
FIGURE 70. GLOBAL TAVI MARKET VALUE, BY REGION 2024-2030, (MILLION USD)
FIGURE 71. NORTH AMERICA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 72. NORTH AMERICA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 73. NORTH AMERICA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 74. NORTH AMERICA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 75. UNITED STATES TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 76. UNITED STATES TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 77. UNITED STATES TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 78. UNITED STATES TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 79. CANADA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 80. CANADA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 81. CANADA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 82. CANADA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 83. MEXICO TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 84. MEXICO TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 85. MEXICO TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 86. MEXICO TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 87. EUROPE TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 88. EUROPE TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 89. EUROPE TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 90. EUROPE TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 91. GERMANY TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 92. GERMANY TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 93. GERMANY TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 94. GERMANY TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 95. FRANCE TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 96. FRANCE TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 97. FRANCE TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 98. FRANCE TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 99. ITALY TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 100. ITALY TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 101. ITALY TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 102. ITALY TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 103. SPAIN TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 104. SPAIN TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 105. SPAIN TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 106. SPAIN TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 107. UNITED KINGDOM TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 108. UNITED KINGDOM TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 109. UNITED KINGDOM TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 110. UNITED KINGDOM TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 111. RUSSIA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 112. RUSSIA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 113. RUSSIA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 114. RUSSIA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 115. SWEDEN TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 116. SWEDEN TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 117. SWEDEN TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 118. SWEDEN TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 119. NORWAY TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 120. NORWAY TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 121. NORWAY TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 122. NORWAY TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 123. DENMARK TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 124. DENMARK TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 125. DENMARK TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 126. DENMARK TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 127. NETHERLANDS TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 128. NETHERLANDS TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 129. NETHERLANDS TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 130. NETHERLANDS TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 131. FINLAND TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 132. FINLAND TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 133. FINLAND TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 134. FINLAND TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 135. REST OF EUROPE TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 136. REST OF EUROPE TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 137. REST OF EUROPE TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 138. REST OF EUROPE TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 139. ASIA-PACIFIC TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 140. ASIA-PACIFIC TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 141. ASIA-PACIFIC TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 142. ASIA-PACIFIC TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 143. AUSTRALIA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 144. AUSTRALIA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 145. AUSTRALIA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 146. AUSTRALIA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 147. CHINA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 148. CHINA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 149. CHINA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 150. CHINA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 151. INDIA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 152. INDIA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 153. INDIA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 154. INDIA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 155. JAPAN TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 156. JAPAN TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 157. JAPAN TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 158. JAPAN TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 159. SOUTH KOREA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 160. SOUTH KOREA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 161. SOUTH KOREA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 162. SOUTH KOREA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 163. INDONESIA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 164. INDONESIA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 165. INDONESIA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 166. INDONESIA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 167. SINGAPORE TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 168. SINGAPORE TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 169. SINGAPORE TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 170. SINGAPORE TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 171. TAIWAN TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 172. TAIWAN TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 173. TAIWAN TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 174. TAIWAN TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 175. THAILAND TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 176. THAILAND TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 177. THAILAND TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 178. THAILAND TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 179. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 180. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 181. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 182. REST OF ASIA-PACIFIC TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 183. REST OF THE WORLD TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 184. REST OF THE WORLD TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 185. REST OF THE WORLD TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 186. REST OF THE WORLD TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 187. LATIN AMERICA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 188. LATIN AMERICA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 189. LATIN AMERICA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 190. LATIN AMERICA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 191. MIDDLE EAST TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 192. MIDDLE EAST TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 193. MIDDLE EAST TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 194. MIDDLE EAST TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 195. AFRICA TAVI MARKET VALUE, BY PRODUCT TYPE 2024-2030, (MILLION USD)
FIGURE 196. AFRICA TAVI MARKET VALUE, BY PROCEDURE 2024-2030, (MILLION USD)
FIGURE 197. AFRICA TAVI MARKET VALUE, BY PATIENT GROUP 2024-2030, (MILLION USD)
FIGURE 198. AFRICA TAVI MARKET VALUE, BY END USER 2024-2030, (MILLION USD)
FIGURE 199. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 200. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 201. MERIL LIFE SCIENCES PVT. LTD.: NET SALES, (2022-2024)
FIGURE 202. MERIL LIFE SCIENCES PVT. LTD.: PRIMARY MARKET COMPETITORS
FIGURE 203. BOSTON SCIENTIFIC CORPORATION: NET SALES, (2022-2024)
FIGURE 204. BOSTON SCIENTIFIC CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 205. LEPU MEDICAL TECHNOLOGY CO., LTD.: NET SALES, (2022-2024)
FIGURE 206. LEPU MEDICAL TECHNOLOGY CO., LTD.: PRIMARY MARKET COMPETITORS
FIGURE 207. NEW VALVE TECHNOLOGY (NVT) GMBH: NET SALES, (2022-2024)
FIGURE 208. NEW VALVE TECHNOLOGY (NVT) GMBH: PRIMARY MARKET COMPETITORS
FIGURE 209. MEDTRONIC PLC: NET SALES, (2022-2024)
FIGURE 210. MEDTRONIC PLC: PRIMARY MARKET COMPETITORS
FIGURE 211. VENUS MEDTECH INC.: NET SALES, (2022-2024)
FIGURE 212. VENUS MEDTECH INC.: PRIMARY MARKET COMPETITORS
FIGURE 213. EDWARDS LIFESCIENCES CORPORATION: NET SALES, (2022-2024)
FIGURE 214. EDWARDS LIFESCIENCES CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 215. MICROPORT SCIENTIFIC CORPORATION: NET SALES, (2022-2024)
FIGURE 216. MICROPORT SCIENTIFIC CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 217. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: NET SALES, (2022-2024)
FIGURE 218. PEIJIA MEDICAL TECHNOLOGY CO., LTD.: PRIMARY MARKET COMPETITORS
FIGURE 219. JENAVALVE TECHNOLOGY, INC.: NET SALES, (2022-2024)
FIGURE 220. JENAVALVE TECHNOLOGY, INC.: PRIMARY MARKET COMPETITORS
FIGURE 221. ANTERIS TECHNOLOGIES: NET SALES, (2022-2024)
FIGURE 222. ANTERIS TECHNOLOGIES: PRIMARY MARKET COMPETITORS
FIGURE 223. SHANGHAI NEWMED MEDICAL CO., LTD.: NET SALES, (2022-2024)
FIGURE 224. SHANGHAI NEWMED MEDICAL CO., LTD.: PRIMARY MARKET COMPETITORS
FIGURE 225. COLIBRI HEART VALVE LLC: NET SALES, (2022-2024)
FIGURE 226. COLIBRI HEART VALVE LLC: PRIMARY MARKET COMPETITORS
FIGURE 227. THUBRIKAR AORTIC VALVE, INC.: NET SALES, (2022-2024)
FIGURE 228. THUBRIKAR AORTIC VALVE, INC.: PRIMARY MARKET COMPETITORS

Research Methodology

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Methodology Nmsc Updated

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

Porters 5 Updated 2

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

What Is the Transcatheter Aortic Valve Implantation (TAVI) Market Size?

The global Transcatheter Aortic Valve Implantation (TAVI) Market size was valued at USD 8.57 billion in 2025 and is estimated at USD 9.87 billion in 2026, forecast to reach USD 21.59 billion by 2035, expanding at a 9.08% CAGR between 2026 and 2035. North America leads with approximately 46% share, while Balloon-Expandable valves dominate all other expansion mechanisms with approximately 48% share.

We observed that growth is distributed across every segmentation axis, with expanding regulatory indications and alternative access route adoption shaping demand through 2035.

Transcatheter Aortic Valve Implantation (TAVI) Market Revenue Forecast

Values in USD Billion

2025 $8.57 Billion

2025

2026 $9.35 Billion

2026

2027 $10.20 Billion

2027

2028 $11.12 Billion

2028

2029 $12.13 Billion

2029

2030 $13.23 Billion

2030

2031 $14.44 Billion

2031

2032 $15.75 Billion

2032

2033 $17.18 Billion

2033

2034 $18.74 Billion

2034

2035 $21.59 Billion

2035

Key Takeaways

By Valve Expansion Mechanism: Balloon-Expandable held the largest share of approximately 48% (USD 4.11 billion) in 2025; Self-Expanding is the fastest-growing sub-segment at 10.1% CAGR from 2026–2035.

By Leaflet Material: Bovine Pericardium held the largest share of approximately 82% (USD 7.02 billion) in 2025; Synthetic Polymer is the fastest-growing sub-segment at 16.4% CAGR from 2026–2035.

By Frame Material: Nitinol Alloy held the largest share of approximately 62% (USD 5.32 billion) in 2025; Other Materials is the fastest-growing sub-segment at 11.9% CAGR from 2026–2035.

By Repositionability: Repositionable held the largest share of approximately 68% (USD 5.83 billion) in 2025; Repositionable is also the fastest-growing sub-segment at 9.8% CAGR from 2026–2035.

By Retrieval Capability: Retrievable held the largest share of approximately 64% (USD 5.48 billion) in 2025; Retrievable is also the fastest-growing sub-segment at 9.8% CAGR from 2026–2035.

By Implantation Access Route: Transfemoral held the largest share of approximately 88% (USD 7.54 billion) in 2025; Transcarotid is the fastest-growing sub-segment at 17.7% CAGR from 2026–2035.

By Target Indication: Native Aortic Stenosis held the largest share of approximately 84% (USD 7.19 billion) in 2025; Native Aortic Regurgitation is the fastest-growing sub-segment at 19.7% CAGR from 2026–2035.

By Patient Surgical Risk: Low Risk held the largest share of approximately 42% (USD 3.60 billion) in 2025; Low Risk is also the fastest-growing sub-segment at 10.7% CAGR from 2026–2035.

By End User Facility: General Hospitals held the largest share of approximately 54% (USD 4.63 billion) in 2025; Ambulatory Surgical Centers is the fastest-growing sub-segment at 14.0% CAGR from 2026–2035.

By Sales Channel: Direct Sales held the largest share of approximately 72% (USD 6.17 billion) in 2025; Distributor Sales is the fastest-growing sub-segment at 10.7% CAGR from 2026–2035.

Dominant Region: North America dominated with approximately 46% revenue share (USD 3.94 billion) in 2025.

Fastest-Growing Region: Asia-Pacific is expected to register the highest CAGR of 12.8% during 2026–2035.

Dominant Country: U.S. led with approximately USD 3.35 billion in 2025.

Fastest-Growing Country: India is the fastest-growing country at approximately 14.7% CAGR from 2026–2035.

Market Opportunity: The Transcatheter Aortic Valve Implantation (TAVI) Market is expected to create an absolute revenue opportunity of USD 11.72 billion between 2026 and 2035, presenting significant investment potential across expanding regulatory indications and alternative access route platforms.

According to NMSC analysis, device manufacturers are increasingly directing research investment toward valve durability and redo-TAVI compatibility rather than first-implant performance alone, a shift that reflects the growing population of patients now living long enough after an initial transcatheter valve to require a second intervention.

What Does the Transcatheter Aortic Valve Implantation (TAVI) Market Encompass?

The Transcatheter Aortic Valve Implantation (TAVI) Market encompasses catheter-delivered prosthetic aortic valves used to treat native aortic stenosis, native aortic regurgitation, and failed surgical or transcatheter bioprosthetic valves without open-chest surgery. We observed that the scope spans balloon-expandable and self-expanding valve platforms, delivered predominantly through transfemoral access, with alternative routes reserved for patients with unsuitable femoral or iliac anatomy. Pre-procedural planning relies on computed tomography-based sizing and echocardiographic assessment of valve anatomy and annular dimensions, while heart teams combining cardiac surgeons and interventional cardiologists determine candidacy across the surgical risk spectrum.
The U.S. Food and Drug Administration's April 2025 approval of the Edwards Lifesciences SAPIEN 3 platform for asymptomatic severe aortic stenosis, following the EARLY TAVR trial, extended the treatable population beyond symptomatic patients for the first time. We observed that regulatory scope is also broadening into native aortic regurgitation, a distinct clinical entity from stenosis that historically lacked a dedicated transcatheter option, and into redo procedures for patients with a previously failed transcatheter valve. NMSC's analysis indicates that this indication expansion, rather than aortic disease prevalence alone, is the direct mechanism driving eligible patient volume across the TAVI Market.

Key Emerging Trends

Based on research conducted by NMSC, we found that four structural trends are reshaping product development, procurement, and clinical adoption across the industry.

How Is Regulatory Expansion Into Asymptomatic Disease Transforming Patient Eligibility?

Regulators are extending TAVI indications beyond symptomatic disease for the first time. We observed that the FDA approved Edwards Lifesciences' SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA platforms in May 2025 for asymptomatic severe aortic stenosis, based on the 901-patient EARLY TAVR trial published in the New England Journal of Medicine, which reported a lower rate of a composite of death, stroke, or unplanned cardiovascular hospitalization with early intervention than with guideline-recommended surveillance. This approval adds a previously ineligible patient segment, requiring heart teams to build earlier-stage surveillance and referral pathways alongside existing symptomatic-patient workflows.

Why Is Redo-TAVI Emerging as a Distinct Clinical and Commercial Category?

A growing number of patients who received a transcatheter valve years ago are now presenting with valve degeneration, creating demand for a dedicated redo pathway. Medtronic received FDA approval in August 2025 for an expanded Redo-TAVR indication covering its Evolut Pro+, FX, and FX+ systems, permitting implantation of a new valve inside a failed transcatheter valve, and the company launched its RESTORE study to track outcomes in up to 225 patients with symptomatic bioprosthetic valve failure. This trend is pushing manufacturers to validate frame and leaflet compatibility for valve-in-valve deployment rather than first-implant use alone.

How Is Dedicated Aortic Regurgitation Treatment Reshaping Device Design?

Native aortic regurgitation lacks the calcification that anchors a conventional transcatheter valve, requiring purpose-built frame and sealing designs rather than stenosis-indicated devices. JenaValve Technology received FDA premarket approval in March 2026 for its Trilogy transcatheter heart valve system, becoming the first and only device with a dedicated U.S. indication for symptomatic severe aortic regurgitation in patients at high or greater surgical risk. Peijia Medical separately received Chinese NMPA approval in December 2025 for its TaurusTrio system, manufactured under exclusive license from JenaValve , extending dedicated regurgitation treatment into China's transfemoral TAVI market.

How Is Alternative Access Route Adoption Expanding Treatment for Femoral-Ineligible Patients?

Not every candidate has femoral or iliac arteries suitable for standard transfemoral delivery, prompting continued use of transapical, transaortic, transcarotid , and transaxillary access. We observed that transcarotid access has gained a growing evidence base as an alternative for patients with unsuitable femoral anatomy who would otherwise require a more invasive transapical or transaortic approach. This trend is elevating demand for delivery systems and sheaths engineered for cervical and axillary vessel navigation among centers treating anatomically complex patients.

Market Drivers & Dynamics

Interactive Dataset


Expanding regulatory indications to asymptomatic severe aortic stenosis	driver	+2.6%	North America	2026-2032
Growing eligible patient population under low-risk and intermediate-risk approvals	driver	+2.1%	Global	2026-2035
Rising redo-TAVI addressable population from earlier-generation valve degeneration	driver	+1.4%	North America, Europe	2026-2035
Emerging dedicated aortic regurgitation indication	driver	+1.2%	Global	2026-2033
Expanding structural heart program capacity and heart team infrastructure	driver	+1.0%	Asia-Pacific, Latin America	2026-2035
Increasing adoption of alternative access routes for femoral-ineligible patients	driver	+0.8%	Global	2026-2032
High device and procedural costs relative to surgical alternatives	restraint	-1.5%	Middle East & Africa, Latin America	2026-2035
Limited structural heart program capacity and specialist availability in emerging markets	restraint	-1.1%	Asia-Pacific, Middle East & Africa	2026-2032
Regulatory and reimbursement heterogeneity across national health systems	restraint	-0.7%	Global	2026-2030

Source: Next Move Strategy Consulting

Growth Drivers

What Is the Primary Growth Driver of the Transcatheter Aortic Valve Implantation (TAVI) Market?

Expanding regulatory indications to asymptomatic severe aortic stenosis is the primary driver of the market. The FDA's April 2025 approval of the Edwards Lifesciences SAPIEN 3 platform for this population, supported by EARLY TAVR trial data, directly enlarges the treatable patient base beyond symptomatic disease for the first time. We observed that this indication expansion, rather than general cardiovascular disease prevalence, is the direct mechanism connecting aortic stenosis diagnosis to procedure volume across referring health systems.

How Is Redo-TAVI Approval Driving Transcatheter Aortic Valve Implantation (TAVI) Market Growth?

Medtronic's August 2025 FDA approval of an expanded Redo-TAVR indication for its Evolut Pro+, FX, and FX+ systems is accelerating market growth by formalizing a treatment pathway for patients with a failed transcatheter valve. NMSC's analysis indicates that this approval, combined with the company's RESTORE outcomes study enrolling up to 225 patients, is compressing the time between valve degeneration diagnosis and a validated redo-TAVI treatment option across health systems with an established structural heart program.

Growth Inhibitors

What Is Restraining Transcatheter Aortic Valve Implantation (TAVI) Market Expansion?

High device and procedural costs relative to surgical alternatives restrain broader adoption across cost-constrained health systems. The U.S. Centers for Medicare & Medicaid Services updated its Medicare National Coverage Determination for TAVR on September 10, 2026, including Coverage with Evidence Development for asymptomatic severe aortic stenosis. We found that limited structural heart program capacity and specialist availability particularly constrain adoption in emerging markets, where fewer certified heart teams and catheterization laboratories are equipped to perform the procedure.

Segmentation Analysis

2025 (USD Billion)

2035 (USD Billion)

Balloon-Expa

Self-Expandi

Other Expans

Bovine Peric

Porcine Tiss

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Balloon-Expandable	$10.0 USD Billion	$40.0 USD Billion	15.0%
Self-Expanding	$17.1 USD Billion	$51.1 USD Billion	17.0%
Other Expansion Mechanisms	$24.2 USD Billion	$62.2 USD Billion	15.0%
Bovine Pericardium	$31.3 USD Billion	$73.3 USD Billion	25.0%
Porcine Tissue	$38.4 USD Billion	$84.4 USD Billion	14.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Valve Expansion Mechanism.

Unlock Full Data

Which Valve Expansion Mechanism Dominates the Transcatheter Aortic Valve Implantation (TAVI) Market?

Balloon-Expandable valves led the market with USD 4.11 billion in 2025, a position built on the intra-annular SAPIEN platform's long clinical track record and its use across the full surgical risk spectrum following successive FDA indication expansions. We observed that Self-Expanding valves are the fastest-growing mechanism, expanding at a 10.1% CAGR from 2026 to 2035, as the supra-annular Evolut platform's repositionable delivery and its August 2025 Redo-TAVR indication broaden its role in both first-time and valve-in-valve procedures.

2025 (USD Billion)

2035 (USD Billion)

Transfemoral

Transapical

Transaortic

Transcarotid

Transaxillar

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Transfemoral	$10.0 USD Billion	$40.0 USD Billion	15.0%
Transapical	$17.1 USD Billion	$51.1 USD Billion	25.0%
Transaortic	$24.2 USD Billion	$62.2 USD Billion	23.0%
Transcarotid	$31.3 USD Billion	$73.3 USD Billion	21.0%
Transaxillary ( Transsubclavian )	$38.4 USD Billion	$84.4 USD Billion	26.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Implantation Access Route.

Unlock Full Data

Which Implantation Access Route Leads Transcatheter Aortic Valve Implantation (TAVI) Market Demand?

Transfemoral access remained the leading route within the market, valued at USD 7.54 billion in 2025, reflecting its status as the default approach whenever femoral and iliac vessel anatomy permits catheter delivery. Our findings suggest that Transcarotid access is the fastest-growing route, registering a 17.7% CAGR from 2026 to 2035, as centers increasingly favor it over more invasive transapical or transaortic surgical cutdown approaches for patients whose femoral anatomy is unsuitable for standard delivery.

2025 (USD Billion)

2035 (USD Billion)

Native Aorti

Surgical Bio

Native Aorti

Previous Tra

Other Aortic

Segment Item	2025 (USD Billion)	2035 (USD Billion)	CAGR
Native Aortic Stenosis	$10.0 USD Billion	$40.0 USD Billion	8.0%
Surgical Bioprosthetic Valve Failure	$17.1 USD Billion	$51.1 USD Billion	14.0%
Native Aortic Regurgitation	$24.2 USD Billion	$62.2 USD Billion	12.0%
Previous Transcatheter Valve Failure	$31.3 USD Billion	$73.3 USD Billion	18.0%
Other Aortic Valve Indications	$38.4 USD Billion	$84.4 USD Billion	9.0%

Segment-wise data is locked

Unlock complete segment-wise numbers for By Target Indication.

Unlock Full Data

Which Target Indication Dominates the Transcatheter Aortic Valve Implantation (TAVI) Market?

Native Aortic Stenosis remained the dominant target indication within the market, valued at USD 7.19 billion in 2025, since it is the original and still-primary approved indication across nearly every commercially available TAVI platform. Our assessment indicates that Native Aortic Regurgitation is the fastest-growing indication, expanding at a 19.7% CAGR from 2026 to 2035, following JenaValve's March 2026 U.S. approval and Peijia Medical's December 2025 China approval of dedicated devices for a population that previously lacked a transcatheter treatment option.

Regulatory Framework Impacting the Transcatheter Aortic Valve Implantation (TAVI) Market

The TAVI market operates within a stringent regulatory environment focused on device safety, clinical efficacy, quality management, and post-market surveillance. Regulatory pathways such as U.S. FDA requirements and EU MDR influence market access, while reimbursement policies shape adoption. In the U.S., CMS updated its Medicare National Coverage Determination for TAVR on September 10, 2026, including Coverage with Evidence Development for asymptomatic severe aortic stenosis . Increasing clinical evidence, standardized quality systems, and regulatory oversight support innovation and broader use of TAVI technologies.

Growth Opportunities

Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within the Transcatheter Aortic Valve Implantation (TAVI) Market over the 2026-2035 forecast period.

How Can Dedicated Aortic Regurgitation Platforms Unlock Value for Device Makers?

Dedicated aortic regurgitation valves present a whitespace opportunity for manufacturers able to engineer anchoring and sealing mechanisms suited to a non-calcified annulus. Companies that commercialize validated regurgitation-specific platforms, following JenaValve's Trilogy approval, stand to capture share among high-surgical-risk patients who previously had no transcatheter alternative to surgical valve replacement or continued medical management.

Where Does Redo-TAVI Create New Demand for Valve Manufacturers?

Redo-TAVI represents an underpenetrated opportunity for manufacturers that validate their platforms for valve-in-valve deployment inside a previously implanted device. Vendors that secure a dedicated redo indication, as Medtronic did for its Evolut systems in August 2025, can capture recurring procedure volume from the expanding population of patients now years removed from their original transcatheter implant.

How Can Alternative Access Route Innovation Benefit Femoral-Ineligible Patients?

Delivery systems engineered for transcarotid and transaxillary navigation create an opportunity for manufacturers to serve patients whose femoral or iliac anatomy disqualifies them from standard transfemoral delivery. Vendors that validate dedicated sheaths and catheter designs for cervical and axillary access can differentiate with structural heart programs seeking to avoid more invasive transapical or transaortic surgical approaches.

Regional Outlook

2025 (USD Billion)

2035 (USD Billion)

North Americ

Europe

Asia-Pacific

Middle East

Latin Americ

Region	2025 (USD Billion)	2035 (USD Billion)	CAGR (%)
North America	$10.0 USD Billion	$40.0 USD Billion	9.0%
Europe	$17.1 USD Billion	$51.1 USD Billion	27.0%
Asia-Pacific	$24.2 USD Billion	$62.2 USD Billion	25.0%
Middle East & Africa	$31.3 USD Billion	$73.3 USD Billion	23.0%
Latin America	$38.4 USD Billion	$84.4 USD Billion	12.0%

Regional data is locked

Unlock complete regional numbers for this market.

Unlock Full Data

North America Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

2025 Size

$3.94 Billion

CAGR

7.4%

North America leads the Transcatheter Aortic Valve Implantation (TAVI) Market on the strength of established Medicare reimbursement, the region's largest concentration of certified structural heart programs, and the FDA's successive indication expansions. We observed that the April 2025 approval for asymptomatic severe aortic stenosis and the August 2025 Redo-TAVI approval both originated in this region before extending internationally. Technology adoption favors both balloon-expandable and self-expanding platforms, with Edwards Lifesciences and Medtronic serving as leading suppliers alongside other TAVI manufacturers .

Primary Driver: Established reimbursement and expanding asymptomatic and redo-TAVI indications

Key National Markets

U.S. Transcatheter Aortic Valve Implantation (TAVI) Market

Based on our estimates, the Transcatheter Aortic Valve Implantation (TAVI) Market in the U.S. was valued at approximately USD 3.35 billion in 2025 and is projected to reach USD 7.15 billion by 2035, growing at a 7.1% CAGR from 2026 to 2035. Demand is anchored by the nation's largest concentration of certified structural heart programs, established Medicare national coverage, and the FDA's successive indication expansions to asymptomatic and redo-TAVI populations. Technology adoption favors both balloon-expandable and self-expanding platforms, and competitive intensity remains high between Edwards Lifesciences Corporation and Medtronic plc, which together anchor the bulk of U.S. procedure volume across the surgical risk spectrum.

Canada Transcatheter Aortic Valve Implantation (TAVI) Market

The market in Canada was valued at approximately USD 0.35 billion in 2025 and is projected to reach USD 0.87 billion by 2035, growing at a 8.9% CAGR from 2026 to 2035. Demand structure mirrors U.S. clinical practice patterns, while provincial health authorities determine procedure funding and hospital-level TAVI program certification. Technology adoption is rising as more provincial cardiac centers establish structural heart teams, with competitive intensity moderate given the market's reliance on the same multinational suppliers active in the United States.

Europe Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

2025 Size

$2.23 Billion

CAGR

7.6%

Europe's Transcatheter Aortic Valve Implantation (TAVI) Market reflects one of the world's most mature structural heart landscapes, supported by broad CE Mark access that has historically preceded U.S. approval for several devices, including JenaValve's Trilogy system in 2021. Our findings suggest that national health systems across Germany, France, and the UK maintain established heart team referral pathways for aortic stenosis, while reimbursement frameworks vary by country and shape the pace of low-risk indication uptake relative to North America.

Primary Driver: Broad CE Mark access and mature structural heart programs

Key National Markets

UK Transcatheter Aortic Valve Implantation (TAVI) Market

As per our estimate, the Transcatheter Aortic Valve Implantation (TAVI) Market in the UK was valued at approximately USD 0.46 billion in 2025 and is projected to reach USD 1.02 billion by 2035, growing at a 7.6% CAGR from 2026 to 2035. Demand is driven by National Health Service structural heart programs operating under nationally coordinated commissioning arrangements for aortic valve disease. Regulatory influence from the UK's post-Brexit medical device framework is notable, and competitive intensity remains high given the concentration of established suppliers serving NHS trusts and private cardiac centers.

Germany Transcatheter Aortic Valve Implantation (TAVI) Market

Based on our estimates, the Transcatheter Aortic Valve Implantation (TAVI) Market in Germany was valued at approximately USD 0.52 billion in 2025 and is projected to reach USD 1.16 billion by 2035, growing at a 7.6% CAGR from 2026 to 2035. Demand is supported by Germany's large network of certified cardiac centers and one of Europe's highest reported TAVI procedure volumes per capita. Regulatory influence from the EU Medical Device Regulation is significant, and technology adoption favors both major valve platforms as domestic and international suppliers compete for the country's structural heart program spending.

France Transcatheter Aortic Valve Implantation (TAVI) Market

According to our analysis, the Transcatheter Aortic Valve Implantation (TAVI) Market in France was valued at approximately USD 0.38 billion in 2025 and is projected to reach USD 0.83 billion by 2035, growing at a 7.4% CAGR from 2026 to 2035. Demand is supported by France's nationally organized heart team referral system for aortic stenosis, which shapes procedure volume growth across public and private cardiac centers. Regulatory influence from French national health authority guidance is notable, and competitive intensity remains high given the concentration of established suppliers serving domestic structural heart programs.

Asia-Pacific Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

2025 Size

$1.71 Billion

CAGR

12.8%

Asia-Pacific is the fastest-growing Transcatheter Aortic Valve Implantation (TAVI) Market region, propelled by expanding structural heart program capacity in China and India alongside NMPA approvals for domestic devices such as Peijia Medical's TaurusTrio . We found that regulatory pathways in the region increasingly support locally developed platforms tailored to regional anatomy and pricing expectations, giving domestic manufacturers a growing role alongside multinational suppliers. Technology adoption is accelerating as more hospitals establish dedicated structural heart teams capable of performing transfemoral procedures.

Primary Driver: Expanding structural heart program capacity and domestic device approvals

Key National Markets

China Transcatheter Aortic Valve Implantation (TAVI) Market

The market in China was valued at approximately USD 0.58 billion in 2025 and is projected to reach USD 2.05 billion by 2035, growing at a 13.3% CAGR from 2026 to 2035, supported by NMPA approvals for domestic manufacturers including Peijia Medical, MicroPort CardioFlow , and Venus Medtech. Regulatory influence from the NMPA increasingly favors devices tailored to regional anatomy, and competitive intensity remains elevated among domestic suppliers expanding structural heart program access beyond major metropolitan centers.

India Transcatheter Aortic Valve Implantation (TAVI) Market

As per our estimate, the Transcatheter Aortic Valve Implantation (TAVI) Market in India was valued at approximately USD 0.36 billion in 2025 and is projected to reach USD 1.42 billion by 2035, growing at a 14.7% CAGR from 2026 to 2035, the fastest among covered countries. Demand structure reflects expanding structural heart program capacity and domestic device availability from manufacturers including Meril Life Sciences and Sahajanand Medical Technologies. Regulatory influence from India's Central Drugs Standard Control Organisation remains developing, while specialist training programs are expanding procedure access beyond tertiary referral centers.

Japan Transcatheter Aortic Valve Implantation (TAVI) Market

According to our analysis, the Transcatheter Aortic Valve Implantation (TAVI) Market in Japan was valued at approximately USD 0.32 billion in 2025 and is projected to reach USD 0.96 billion by 2035, growing at a 11.2% CAGR from 2026 to 2035. Demand is supported by Japan's established national health insurance system, which provides broad reimbursement coverage for TAVI procedures across an aging population. Regulatory influence from the Pharmaceuticals and Medical Devices Agency is well established, technology adoption is advanced, and competitive intensity remains high among long-standing multinational suppliers serving Japan's structural heart programs.

South Korea Transcatheter Aortic Valve Implantation (TAVI) Market

Based on our estimates, the Transcatheter Aortic Valve Implantation (TAVI) Market in South Korea was valued at approximately USD 0.18 billion in 2025 and is projected to reach USD 0.55 billion by 2035, growing at a 11.5% CAGR from 2026 to 2035. Demand structure benefits from South Korea's national health insurance coverage for TAVI procedures and a concentrated network of tertiary cardiac centers. Technology adoption is high, with established multinational platforms supplying most procedure volume, and competitive intensity remains pronounced amid growing referral volume tied to national health screening programs for elderly patients.

Australia Transcatheter Aortic Valve Implantation (TAVI) Market

The Transcatheter Aortic Valve Implantation (TAVI) Market in Australia was valued at approximately USD 0.09 billion in 2025 and is projected to reach USD 0.27 billion by 2035, growing at a 11.2% CAGR from 2026 to 2035. Demand is supported by Australia's Medicare Benefits Schedule coverage for TAVI procedures and a growing number of accredited structural heart centers. Regulatory influence stems from the Therapeutic Goods Administration's device approval framework, while technology adoption favors established multinational platforms amid moderate competitive intensity across public and private hospital networks.

Middle East & Africa Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

2025 Size

$0.43 Billion

CAGR

11.3%

The Transcatheter Aortic Valve Implantation (TAVI) Market in Middle East & Africa is expanding as Gulf Cooperation Council health systems invest in specialist training and referral network development to support structural heart programs. Our analysis shows that Saudi Arabia and the UAE are establishing dedicated cardiac centers capable of performing TAVI procedures, supported by government healthcare investment tied to national health sector development plans. Regulatory pathways generally follow device approvals already granted in Europe or the United States, and technology adoption remains concentrated in a small number of specialized centers.

Primary Driver: Growing specialist training and referral network development

Key National Markets

Saudi Arabia Transcatheter Aortic Valve Implantation (TAVI) Market

According to our analysis, the Transcatheter Aortic Valve Implantation (TAVI) Market in Saudi Arabia was valued at approximately USD 0.11 billion in 2025 and is projected to reach USD 0.35 billion by 2035, growing at a 12.0% CAGR from 2026 to 2035. Demand is driven by Vision 2030-linked healthcare infrastructure investment and expanding specialist cardiology training programs. Regulatory influence is developing under the Saudi Food and Drug Authority's medical device framework, and technology adoption is advancing as domestic and international suppliers scale delivery capacity for growing structural heart program demand.

UAE Transcatheter Aortic Valve Implantation (TAVI) Market

As per our estimate, the Transcatheter Aortic Valve Implantation (TAVI) Market in UAE was valued at approximately USD 0.09 billion in 2025 and is projected to reach USD 0.29 billion by 2035, growing at a 12.1% CAGR from 2026 to 2035. Demand structure is shaped by the UAE's investment in specialized cardiac centers tied to national healthcare development plans. Regulatory pathways generally reference prior FDA or CE Mark approvals rather than requiring independent trials, technology adoption is improving through imported multinational platforms, and competitive intensity is rising as suppliers expand delivery portfolios to serve Gulf referral centers.

South Africa Transcatheter Aortic Valve Implantation (TAVI) Market

Based on our estimates, the Transcatheter Aortic Valve Implantation (TAVI) Market in South Africa was valued at approximately USD 0.06 billion in 2025 and is projected to reach USD 0.18 billion by 2035, growing at a 11.2% CAGR from 2026 to 2035. Demand structure reflects a developing structural heart program base serving regional Southern African referral patterns. Regulatory influence stems from the South African Health Products Regulatory Authority's device registration requirements, technology adoption is gradually improving, and competitive intensity is limited given reliance on imported platforms from Europe and North America.

Latin America Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

2025 Size

$0.26 Billion

CAGR

12.3%

Latin America's Transcatheter Aortic Valve Implantation (TAVI) Market is supported by rising structural heart program investment in Brazil and Argentina and expanding device registration activity, including Venus Medtech's regulatory approvals for its Venus- PowerX system in Argentina, Chile, and Venezuela. We observed that regulatory frameworks generally reference prior European or U.S. approvals rather than requiring independent clinical programs. Technology adoption remains concentrated in major metropolitan referral centers, with competitive intensity rising as additional device registrations reach the region.

Primary Driver: Rising structural heart program investment and device registration activity

Key National Markets

Brazil Transcatheter Aortic Valve Implantation (TAVI) Market

The market in Brazil was valued at approximately USD 0.13 billion in 2025 and is projected to reach USD 0.44 billion by 2035, growing at a 12.7% CAGR from 2026 to 2035. Demand is underpinned by Brazil's large domestic cardiac care network and expanding structural heart program investment, including regulatory approvals secured by Venus Medtech for its Venus- PowerX system in neighboring Latin American markets. Regulatory influence stems from ANVISA device registration requirements, technology adoption favors established multinational platforms, and competitive intensity remains moderate among regional distributors.

Argentina Transcatheter Aortic Valve Implantation (TAVI) Market

As per our estimate, the Transcatheter Aortic Valve Implantation (TAVI) Market in Argentina was valued at approximately USD 0.05 billion in 2025 and is projected to reach USD 0.16 billion by 2035, growing at a 12.0% CAGR from 2026 to 2035. Demand structure is supported by steady structural heart program development despite macroeconomic volatility affecting import procurement timelines. Regulatory influence remains limited, technology adoption is modest, and competitive intensity is centered on a small number of regional distributors serving domestic cardiac center contracts.

PESTEL Analysis of the Transcatheter Aortic Valve Implantation (TAVI) Market

The TAVI market is shaped by interconnected political, economic, social, technological, environmental, and legal factors. Government healthcare policies, reimbursement frameworks, an aging population, and demand for minimally invasive treatment support market expansion. Meanwhile, advances in valve design, imaging, and digital technologies, alongside regulatory and sustainability requirements, continue to influence innovation, accessibility, and long-term market development.

Competitive Landscape

We observed that the Transcatheter Aortic Valve Implantation (TAVI) Market features a concentrated competitive landscape at the global level, with a small number of multinational device makers competing alongside an expanding group of Asia-based manufacturers on regulatory breadth, indication coverage, and access route versatility.

Dimension	Description
Market Structure	Concentrated among a small number of multinational manufacturers holding the broadest regulatory indication coverage, alongside a growing cohort of China- and India-based manufacturers serving domestic and export markets.
Innovation Focus	Dedicated aortic regurgitation platforms, redo-TAVI compatibility, and alternative access route delivery systems dominate current innovation pipelines across leading manufacturers.
M&A Activity	Selective transaction activity, exemplified by Edwards Lifesciences' proposed acquisition of JenaValve Technology, which was abandoned in January 2026 following a Federal Trade Commission preliminary injunction on antitrust grounds.

How Do Companies Compete in the Transcatheter Aortic Valve Implantation (TAVI) Market?

Companies compete primarily on regulatory indication breadth, clinical trial evidence, and access route versatility across the industry. Edwards Lifesciences Corporation and Medtronic plc leverage decades of accumulated clinical data and the broadest approved indications to serve health systems across the surgical risk spectrum, while manufacturers such as Meril Life Sciences Private Limited and Peijia Medical Limited compete on regional regulatory approvals and pricing suited to domestic reimbursement environments.

Which Competitive Archetypes Dominate the Transcatheter Aortic Valve Implantation (TAVI) Market?

Two archetypes dominate the market: multinational manufacturers with broad, multi-indication regulatory approval spanning aortic stenosis, redo-TAVI, and aortic regurgitation, and regionally focused manufacturers competing on domestic regulatory approval and localized pricing. Edwards Lifesciences Corporation and Medtronic plc exemplify the multinational archetype through indication breadth across surgical risk categories, while Venus Medtech (Hangzhou) Inc. and Peijia Medical Limited exemplify the regional archetype through NMPA-approved platforms tailored to Chinese and export markets.

How Are Companies Differentiating Through Innovation in Transcatheter Aortic Valve Implantation?

Innovation and differentiation strategy increasingly center on indication breadth beyond aortic stenosis and compatibility with prior transcatheter implants. JenaValve Technology's Trilogy system and Peijia Medical's licensed TaurusTrio system both target dedicated aortic regurgitation treatment, while Medtronic's Redo-TAVR indication targets patients with a previously failed transcatheter valve. Our analysis shows that manufacturers unable to demonstrate a validated indication beyond first-implant aortic stenosis risk losing share as heart teams increasingly evaluate device-specific indication coverage during valve selection.

What M&A and Expansion Activity Is Shaping the Transcatheter Aortic Valve Implantation (TAVI) Market?

Regulatory scrutiny of consolidation attempts is shaping competitive structure within the industry. The Federal Trade Commission sued in August 2025 to block Edwards Lifesciences' proposed acquisition of JenaValve Technology, arguing the two companies were the only ones evaluating transcatheter aortic regurgitation treatment in the United States, and Edwards abandoned the deal in January 2026 after a federal judge granted a preliminary injunction. Edwards has instead continued independent development of its Sojourn transcatheter valve and its acquired J-Valve system for aortic regurgitation.

Key Market Players

Our assessment indicates that the following 15 companies are actively shaping valve design, regulatory indication expansion, and access route innovation within the global Transcatheter Aortic Valve Implantation (TAVI) Market.

Edwards Lifesciences Corporation Medtronic plc Abbott Laboratories Venus Medtech (Hangzhou) Inc. Peijia Medical Limited MicroPort CardioFlow Medtech Corporation Meril Life Sciences Private Limited Lepu Medical Technology (Beijing) Co., Ltd. BlueSail Medical Co., Ltd. Sahajanand Medical Technologies Limited Genesis MedTech JenaValve Technology, Inc. Shanghai NewMed Medical Co., Ltd. Beijing Balance Medical Technology Co., Ltd. Braile Biomédica

Latest Developments

We found that recent regulatory approvals and product milestones within the Transcatheter Aortic Valve Implantation (TAVI) Market are concentrated on indication expansion beyond first-implant aortic stenosis, reflecting the industry's broader shift toward redo-TAVI and aortic regurgitation treatment.

Date	Event
August 3, 2026	MicroPort CardioFlow announced first VitaFlow Liberty TAVI procedures in Germany, extending commercial use into another major European valve market. The rollout follows launches across multiple European countries and demonstrates broader physician adoption of a retrievable TAVI platform, strengthening the company’s international competitive position in transcatheter aortic valve therapy.
May 20, 2026	Medtronic reported three-year SMART Trial results showing superior individual and composite hemodynamic measures for Evolut TAVR versus SAPIEN in patients with small aortic annuli. The evidence strengthens differentiation of Medtronic’s self-expanding platform in an anatomically challenging population and can influence valve selection, supporting competitive positioning within the TAVI market.
April 1, 2026	JenaValve announced the U.S. commercial launch of Trilogy, following FDA premarket approval for symptomatic severe native aortic regurgitation in high-risk surgical patients. The first commercial procedures were performed at three U.S. centers, establishing a dedicated transcatheter option for severe AR and expanding the addressable TAVI market beyond aortic stenosis.
January 6, 2026	MicroPort CardioFlow announced VitaFlow Liberty’s first entry into Africa after receiving market approval in Morocco. The company said its TAVI products had entered 35 countries and regions, with more than 800 hospitals and over 17,000 patients reached, indicating expanding international commercialization and broader competitive pressure in emerging TAVI markets.

Expert Insights

Larry Wood

CVP and Group President, Transcatheter Aortic Valve Replacement and Surgical | Edwards Lifesciences

"“The future of TAVR remains strong driven by greater awareness, patient access, advances in new technologies, as well as indication expansion and increased global adoption,”"

Analyst Interpretation

The statement highlights the key structural factors supporting continued growth in the TAVI market. Increasing awareness and patient access can expand diagnosis and treatment rates, while advances in valve technologies can improve clinical outcomes. Indication expansion, particularly toward earlier intervention and broader-risk patient groups, together with increasing global adoption, can further enlarge the addressable TAVI patient population.

Investment Opportunities

What Capital Inflows Are Targeting the Transcatheter Aortic Valve Implantation (TAVI) Market?

Capital inflows into the market are increasingly directed toward dedicated aortic regurgitation platforms and redo-TAVI clinical evidence generation. Peijia Medical's interim 2026 results reported first-ever profit before tax alongside 36.5% year-over-year growth in transcatheter aortic valve replacement implantation volume, reflecting sustained commercial investment behind its TaurusTrio regurgitation platform. We observed that investors favor manufacturers demonstrating validated regulatory indication breadth, viewing approval scope as a proxy for long-term procedure volume growth.

How Is Infrastructure Investment Supporting Transcatheter Aortic Valve Implantation (TAVI) Deployment?

Infrastructure investment is expanding structural heart program capacity and catheterization laboratory capability across Asia-Pacific, the Middle East, and Latin America to serve rising procedure demand. Our findings suggest that manufacturers are supporting heart team training and proctoring programs as hospitals establish new structural heart programs, particularly in markets where certified specialist availability, rather than device access alone, remains the binding constraint on procedure volume growth.

What ESG Considerations Are Shaping Transcatheter Aortic Valve Implantation (TAVI) Investment Decisions?

Environmental, social, and governance considerations relevant to the industry center on equitable access to structural heart programs across income levels and geographies rather than manufacturing-specific environmental metrics. We found that expanding reimbursement coverage and specialist training programs in underserved regions are increasingly viewed by investors as indicators of durable, broad-based procedure volume growth rather than concentration in a small number of high-income markets.

Key Benefits for Stakeholders

How Does This Report Benefit Enterprise and Industry Leaders?

Enterprise and industry leaders gain access to validated segmentation, competitive benchmarking, and regional demand forecasts that support product-portfolio and regulatory-strategy decisions across the Transcatheter Aortic Valve Implantation (TAVI) industry. Our analysis shows that detailed access route, target indication, and patient surgical risk breakdowns help program managers align device development with expanding regulatory indications while identifying underserved segments for portfolio expansion.

How Does This Report Benefit Investors and Financial Analysts?

Investors and financial analysts benefit from consistent, single-point market size and CAGR estimates that support valuation and capital-allocation decisions across the Transcatheter Aortic Valve Implantation (TAVI) Market supply chain. We observed that the report's regional and segment-level growth differentials help identify which manufacturers are best positioned to capture above-market growth in aortic regurgitation and Asia-Pacific categories through 2035.

How Does This Report Benefit Technology Vendors and Product Teams?

Technology vendors and product teams gain insight into emerging design requirements, including redo-TAVI compatibility, dedicated regurgitation sealing mechanisms, and alternative access route delivery systems, that are reshaping the industry. Our findings suggest that this analysis helps R&D teams prioritize development roadmaps around indication expansion and access route versatility increasingly required by heart team device selection processes.

Key Market Segments Evaluated

By Valve Expansion Mechanism

Balloon-Expandable
Self-Expanding
Other Expansion Mechanisms

By Implantation Access Route

Transfemoral
Transapical
Transaortic
Transcarotid
Transaxillary ( Transsubclavian )
Other Access Routes

By Target Indication

Native Aortic Stenosis
Surgical Bioprosthetic Valve Failure
Native Aortic Regurgitation
Previous Transcatheter Valve Failure
Other Aortic Valve Indications

Conclusion & Recommendations

The long-term outlook for the market remains positive, with global revenue projected to more than double from USD 8.57 billion in 2025 to USD 21.59 billion by 2035. The market is projected to grow at a CAGR of 9.08% from 2026 to 2035. We observed that sustained regulatory indication expansion into asymptomatic disease, redo-TAVI, and native aortic regurgitation will continue underpinning demand across the surgical risk spectrum through the forecast period.

What Strategic Positioning Should Transcatheter Aortic Valve Implantation (TAVI) Manufacturers Pursue?

Manufacturers should prioritize regulatory indication breadth beyond first-implant aortic stenosis while pursuing alternative access route compatibility to serve anatomically complex patients. Our assessment indicates that manufacturers investing early in redo-TAVI validation and dedicated aortic regurgitation platforms are positioned to capture premium pricing within the Transcatheter Aortic Valve Implantation (TAVI) Market.

How Attractive Is the Transcatheter Aortic Valve Implantation (TAVI) Market for New Investment?

The Transcatheter Aortic Valve Implantation (TAVI) industry presents an attractive investment case, supported by a USD 11.72 billion absolute revenue opportunity between 2026 and 2035 and above-average growth in Asia-Pacific and aortic regurgitation categories. We found that investment attractiveness is highest for manufacturers combining broad regulatory indication coverage with structural heart program training capacity, positioning them to serve both established and emerging markets simultaneously.

What Market Shifts and Key Risks Should Stakeholders Monitor?

Stakeholders should monitor high device and procedural costs relative to surgical alternatives, limited structural heart program capacity in emerging markets, and regulatory heterogeneity across national health systems as key risks to the Transcatheter Aortic Valve Implantation (TAVI) Market. Our analysis shows that manufacturers unable to demonstrate validated indication breadth risk losing share to competitors with certified redo-TAVI and aortic regurgitation platforms as heart team selection criteria continue to broaden.

What Are the Key Growth Pathways for the Transcatheter Aortic Valve Implantation (TAVI) Market?

Key growth pathways include expanding dedicated aortic regurgitation platform portfolios, scaling redo-TAVI clinical evidence generation, and deepening structural heart program penetration across Asia-Pacific and Latin America. NMSC's analysis indicates that manufacturers pursuing these pathways while maintaining cost competitiveness in core transfemoral aortic stenosis categories are positioned to capture the Transcatheter Aortic Valve Implantation (TAVI) Market's projected growth through 2035.

FAQs

About the Author

Mihul Sharma

Mihul Sharma is Research Associate at Next Move Strategy Consulting, where he has covered technology, industrial, and healthcare markets for 3 years. His work applies structured business research, market analysis, and secondary-source review to assess market trends, competitive developments, and growth opportunities. He supports report development by fully synthesizing industry data, company information, and market signals into concise findings for strategy and investment-focused research teams.

About the Reviewer

Supradip Baul

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

Testimonials

View All Testimonials

SEMIH KAVAKLIOGLU

Co-Founder & Sales Manager

I work a lot in the marketing industry and I know that research is an essential part of any campaign. I have used Market research reports for my own products and I found them to be very informative and well-researched. The team here produces insightful reports for a good price

MELANIE SAMKO

Director of Marketing

The information provided by NMSC is incredibly valuable, thank you so much for such a excellent work. I really appreciate it. I will make sure to reference all of it, in my summary document.

ROBERT SEAN TREVINO

Sr. Director, Head of Strategic Insights & Analytics

I realized that it was a reliable source of information. These days, there are many people who are looking for authentic data, and this is one of the only sources that can offer them with what they need;

PRATYUSH KUMAR DAS

Assistant Manager

We would like to express our appreciation for the data and insights provided by nextmsc. We are very pleased with the quality and depth of the information, which has proven to be highly valuable and beneficial for our business decision-making.

HENRI KNYPHAUSEN

Partner at Singulier [Ex-BCG]

I recently engaged NEXTMSC.com for a commercial due diligence project within the intralogistics sector, and I am pleased to provide a reference based on my experience. In utilizing NEXTMSC.com's services, I found their report to offer valuable insights into market dynamics and key industry players. The initial report provided a solid foundation for our analysis. However, as we were investigating a smaller target in the market, and I had specific customization requests requiring additional research. These requests included detailed information on product portfolios of various players and sub-market sizes, both inclusive and exclusive of certain product categories. NEXTMSC.com demonstrated commendable responsiveness and agility in accommodating these customization requests. Within a timeframe of 1-2 weeks, they delivered a revised report that met our specific needs. Furthermore, they were receptive to my follow-up inquiries, ensuring clarity and understanding of the data provided. The final deliverable significantly contributed to our due diligence efforts. One of NEXTMSC.com's notable strengths lies in their qualitative research capabilities. However, for future engagements, I would recommend the inclusion of a quantified market model in Excel format. Such a model would offer the ability to conduct in-depth analyses and explore various market segments, including country-specific data and subcomponent breakdowns. Based on my positive experience, I would not hesitate to work with NEXTMSC.com again. Their responsiveness, willingness to accommodate customization requests, and commitment to delivering actionable insights make them a reliable partner for commercial research projects.

Transcatheter Aortic Valve Implantation (TAVI) Market

Select License

Table of Contents

1. INTRODUCTION

2. TAVI MARKET – EXECUTIVE SUMMARY

3. PORTER’S FIVE FORCE MODEL ANALYSIS

4. MARKET SHARE ANALYSIS

5. MARKET DYNAMICS

6. GLOBAL TAVI MARKET BY PRODUCT TYPE

7. GLOBAL TAVI MARKET BY PROCEDURE

8. GLOBAL TAVI MARKET BY PATIENT GROUP

9. GLOBAL TAVI MARKET BY END USER

10. GLOBAL TAVI MARKET, BY REGION

11. COMPANY PROFILES

12. LIST OF TABLES

13. LIST OF FIGURES

Research Methodology

Qualitative Approach

Our Specialized Toolbox for Industry-Specific Market Research

Information Procurement

Market Research Approach

Porters Five Forces Analysis

SWOT Analysis

Forecasting

What Is the Transcatheter Aortic Valve Implantation (TAVI) Market Size?

Transcatheter Aortic Valve Implantation (TAVI) Market Revenue Forecast

Key Takeaways

What Does the Transcatheter Aortic Valve Implantation (TAVI) Market Encompass?

Key Emerging Trends

How Is Regulatory Expansion Into Asymptomatic Disease Transforming Patient Eligibility?

Why Is Redo-TAVI Emerging as a Distinct Clinical and Commercial Category?

How Is Dedicated Aortic Regurgitation Treatment Reshaping Device Design?

How Is Alternative Access Route Adoption Expanding Treatment for Femoral-Ineligible Patients?

Market Drivers & Dynamics

Growth Drivers

What Is the Primary Growth Driver of the Transcatheter Aortic Valve Implantation (TAVI) Market?

How Is Redo-TAVI Approval Driving Transcatheter Aortic Valve Implantation (TAVI) Market Growth?

Growth Inhibitors

What Is Restraining Transcatheter Aortic Valve Implantation (TAVI) Market Expansion?

Segmentation Analysis

Which Valve Expansion Mechanism Dominates the Transcatheter Aortic Valve Implantation (TAVI) Market?

Which Implantation Access Route Leads Transcatheter Aortic Valve Implantation (TAVI) Market Demand?

Which Target Indication Dominates the Transcatheter Aortic Valve Implantation (TAVI) Market?

Regulatory Framework Impacting the Transcatheter Aortic Valve Implantation (TAVI) Market

Growth Opportunities

How Can Dedicated Aortic Regurgitation Platforms Unlock Value for Device Makers?

Where Does Redo-TAVI Create New Demand for Valve Manufacturers?

How Can Alternative Access Route Innovation Benefit Femoral-Ineligible Patients?

Regional Outlook

North America Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

Key National Markets

Europe Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

Key National Markets

Asia-Pacific Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

Key National Markets

Middle East & Africa Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

Key National Markets

Latin America Transcatheter Aortic Valve Implantation (TAVI) Market Outlook

Key National Markets

PESTEL Analysis of the Transcatheter Aortic Valve Implantation (TAVI) Market

Competitive Landscape

How Do Companies Compete in the Transcatheter Aortic Valve Implantation (TAVI) Market?

Which Competitive Archetypes Dominate the Transcatheter Aortic Valve Implantation (TAVI) Market?

How Are Companies Differentiating Through Innovation in Transcatheter Aortic Valve Implantation?

What M&A and Expansion Activity Is Shaping the Transcatheter Aortic Valve Implantation (TAVI) Market?

Key Market Players

Latest Developments

Expert Insights

Larry Wood

Analyst Interpretation

Investment Opportunities

What Capital Inflows Are Targeting the Transcatheter Aortic Valve Implantation (TAVI) Market?

How Is Infrastructure Investment Supporting Transcatheter Aortic Valve Implantation (TAVI) Deployment?

What ESG Considerations Are Shaping Transcatheter Aortic Valve Implantation (TAVI) Investment Decisions?

Key Benefits for Stakeholders

How Does This Report Benefit Enterprise and Industry Leaders?

How Does This Report Benefit Investors and Financial Analysts?

How Does This Report Benefit Technology Vendors and Product Teams?

Key Market Segments Evaluated

By Valve Expansion Mechanism